Is Curaleaf Stock a Buy With Its Attempted Hostile Takeover of Aurora Cannabis Under Way?

Curaleaf launched a hostile takeover bid for Aurora Cannabis (ACB) on August 18, 2026, offering $4 per share—a 45% premium to the prevailing market price—with potential to reach $5 per share. ACB shares currently trade below the $4 offer price, signaling investor doubt about deal completion.

A Motley Fool analyst recommends avoiding Curaleaf stock despite the acquisition attempt. The analyst cites three specific concerns: regulatory mismatches between U.S. and Canadian cannabis markets, complications arising from international distribution networks, and the absence of a proven profitability track record at either company.

The discount between ACB's trading price and the $4 offer represents a significant arbitrage spread, typically interpreted as market skepticism about regulatory approval or deal financing. The potential $5 per share ceiling depends on unspecified conditions not detailed in the initial bid announcement.